This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2005.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2005
Title: Katherine Knappenberger: Innovator in T Cell Mediated Treatments
Introduction
Katherine Knappenberger is a notable inventor based in Wilmington, Delaware. She has made significant contributions to the field of medical research, particularly in the development of treatments for T cell mediated conditions.
Latest Patents
Katherine holds a patent for "Cd45 inhibitors - Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection." This innovative patent addresses critical health issues by providing compositions that can potentially improve treatment outcomes for patients suffering from these conditions.
Career Highlights
Katherine is associated with AstraZeneca AB, where she applies her expertise in pharmaceutical research and development. Her work focuses on creating effective solutions for complex medical challenges.
Collaborations
Katherine has collaborated with esteemed colleagues, including Marc Chapdelaine and Gary Steelman, to advance her research and innovations in the field.
Conclusion
Katherine Knappenberger's contributions to medical research and her innovative patent highlight her role as a key figure in the development of treatments for T cell mediated conditions. Her work continues to inspire advancements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile